A Marie Skłodowska-Curie (MCSA) postdoctoral position at Lund University 
Medical Faculty, Sweden.
Structural and biophysical studies of the molecular pathology underlying 
transthyretin amyloidosis (ATTR amyloidosis)

Transthyretin (TTR) amyloidosis is a serious disease that has devastating 
effects on human health. This occurs when the transthyretin protein, which 
normally functions as a blood transporter of the hormone thyroxine and retinal 
binding protein, misfolds and forms amyloid fibrils that obstruct crucial 
tissues such as the heart or nervous tissue.
The project will focus on probing the molecular factors underlying the 
instability of TTR  (see for example 
https://www.nature.com/articles/s41467-019-08609-z/), and in understanding the 
pathway that links the functional and pathological forms of the protein. There 
is also interest in studying the effect of candidate drugs that may slow or 
prevent amyloid formation.

Techniques involved will include X-ray and neutron crystallography, small-angle 
scattering (SAXS & SANS), and cryo-EM. The successful applicant will have good 
access to advanced international facility centres for synchrotron X-ray and 
neutron beams such as MAX IV<https://www.maxiv.lu.se/>, 
ILL<https://www.ill.eu/>, ESRF<https://esrf.fr/>, 
ISIS<https://www.isis.stfc.ac.uk/>, and during the course of this project, 
ESS<https://ess.eu/>.

For further details and  application instructions, see 
https://www.ambercofund.eu/. Applicants are strongly encouraged to contact the 
PI for the project, Professor Trevor Forsyth 
([email protected]<mailto:[email protected]>) before applying.
Deadline:  28th September 2025.


########################################################################

To unsubscribe from the CCP4BB list, click the following link:
https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB&A=1

This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list 
hosted by www.jiscmail.ac.uk, terms & conditions are available at 
https://www.jiscmail.ac.uk/policyandsecurity/

Reply via email to